1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Abdominal Obesity-Pipeline Insights, 2017

Abdominal Obesity-Pipeline Insights, 2017

  • January 2017
  • -
  • Delve Insight


DelveInsight’s, “ Abdominal Obesity-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Abdominal Obesity. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Abdominal Obesity. DelveInsight’s Report also assesses the Abdominal Obesity therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope

- The report provides competitivepipeline landscape of Abdominal Obesity
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Abdominal Obesity pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Abdominal Obesity and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Abdominal Obesity-Pipeline Insights, 2017
Illustrative

- Abdominal Obesity Overview
- Abdominal Obesity Pipeline Therapeutics
- Abdominal Obesity Therapeutics under Development by Companies
- Abdominal Obesity Filed and Phase III Products
- Comparative Analysis
- Abdominal Obesity Phase II Products
- Comparative Analysis
- Abdominal Obesity Phase I and IND Filed Products
- Comparative Analysis
- Abdominal Obesity Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Abdominal Obesity - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Abdominal Obesity - Discontinued Products
- Abdominal Obesity - Dormant Products
- Companies Involved in Therapeutics Development for Abdominal Obesity
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Abdominal Obesity, 2017
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2017
- Comparative Analysis Phase II Products, 2017
- Comparative Analysis Phase I and IND Filed Products, 2017
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
- Drug Candidates Profiles
- Abdominal Obesity Assessment by Monotherapy Products
- Abdominal Obesity Assessment by Combination Products
- Abdominal Obesity Assessment by Route of Administration
- Abdominal Obesity Assessment by Stage and Route of Administration
- Abdominal Obesity Assessment by Molecule Type
- Abdominal Obesity Assessment by Stage and Molecule Type
- Abdominal Obesity Therapeutics - Discontinued Products
- Abdominal Obesity Therapeutics - Dormant Products
- Products under Development by Companies, 2017


List of Figures

- Number of Products under Development for Abdominal Obesity, 2017
- Filed and Phase III Products, 2017
- Phase II Products, 2017
- Phase I and IND Filed Products, 2017
- Discovery and Pre-Clinical Stage Products, 2017
- Abdominal Obesity Assessment by Monotherapy Products
- Abdominal Obesity Assessment by Combination Products
- Abdominal Obesity Assessment by Route of Administration
- Abdominal Obesity Assessment by Stage and Route of Administration
- Abdominal Obesity Assessment by Molecule Type
- Abdominal Obesity Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Human Microbiome Market by Indication, Application, Product, Product Research, Technology Research - Global Forecast to 2025

Human Microbiome Market by Indication, Application, Product, Product Research, Technology Research - Global Forecast to 2025

  • $ 5650
  • Industry report
  • March 2017
  • by MarketsandMarkets

The global human microbiome market is estimated to reach USD 899.1 million by 2025, growing at a CAGR of 21.1% during the forecast period (2022–2025) Factors such as increased focus on human microbiome ...

Global Anti-Obesity Drugs Market - Growth, Trends & Forecast (2017 - 2022)

Global Anti-Obesity Drugs Market - Growth, Trends & Forecast (2017 - 2022)

  • $ 4250
  • Industry report
  • February 2017
  • by Mordor Intelligence LLP

The Global market for Anti-Obesity drugs Market is expected to reach $XX by the end of 2020 growing at a CAGR of around XX% from 2015 to 2021. Obesity generally refers to a condition where a person is ...

EpiCast Report: Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2025

EpiCast Report: Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2025

  • $ 3995
  • Industry report
  • December 2016
  • by GlobalData

EpiCast Report: Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2025 Summary Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence ...

Obesity-api Insights, 2017

January 2017 $ 1250

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.